# Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

> **NCT00506948** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Hematological Malignancies
- Myelodysplastic Syndrome
- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Mycophenolate Mofetil (MMF)
- **DRUG:** Thymoglobulin
- **DRUG:** Sirolimus
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT00506948
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Halted due to high incidence of veno-oclusive disease of the liver.
- **Last updated:** 2020-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00506948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00506948, "Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00506948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*